Home  |  Contact

Cellosaurus BT-549-Dox (CVCL_UJ22)

[Text version]

Cell line name BT-549-Dox
Accession CVCL_UJ22
Resource Identification Initiative To cite this cell line use: BT-549-Dox (RRID:CVCL_UJ22)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Misspelling: HTB-122-Dox; Based on the ATCC catalog number of the parent cell line.
Sequence variations CLTC-VMP1 gene fusion (from parent cell line).
Homozygous for PTEN p.Val275fs*1 (c.821delG) (from parent cell line).
Homozygous for RB1 c.265_607del343 (from parent cell line).
Homozygous for TP53 p.Arg249Ser (c.747G>T) (ClinVar=VCV000012352) (from parent cell line).
Disease Invasive ductal carcinoma, not otherwise specified (NCIt: C4194)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1092 (BT-549)
Sex of cell Female
Age at sampling 72Y
Category Cancer cell line
Publications

PubMed=7902062
de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T., Mannervik B., Bergh J.
Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
Anticancer Res. 13:1425-1430(1993)

Cross-references
Other Wikidata; Q93432704
Entry history
Entry creation25-Feb-2019
Last entry update02-Jul-2020
Version number3